- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ARTIVA BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 12.12.25 | Artiva Biotherapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 12.11.25 | Artiva BioTherapeutics GAAP EPS of -$0.88 | 3 | Seeking Alpha | ||
| 12.11.25 | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK in Autoimmune Disease | 202 | GlobeNewswire (Europe) | 32 patients with autoimmune disease treated with AlloNK plus anti-CD20 monoclonal antibody (mAb) as of October 1, 2025, data cutoff All patients received AlloNK as outpatients, and the majority were... ► Artikel lesen | |
| 12.11.25 | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights | 122 | GlobeNewswire (Europe) | Over 100 patients treated with AlloNK across autoimmune and oncology indications Refractory rheumatoid arthritis (RA) prioritized as lead indication following FDA Fast Track Designation for AlloNK®... ► Artikel lesen | |
| 12.11.25 | Artiva Biotherapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 12.11.25 | Artiva Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 17.10.25 | Cantor Fitzgerald reiterates Overweight rating on Artiva Biotherapeutics stock | 18 | Investing.com | ||
| 16.10.25 | Rheumatoide Arthritis: Artiva erhält FDA Fast-Track-Status für Zelltherapie AlloNK | 5 | Investing.com Deutsch | ||
| 16.10.25 | Artiva Biotherapeutics stock soars after FDA Fast Track designation | 2 | Investing.com | ||
| 16.10.25 | Artiva's AlloNK receives FDA Fast Track status for rheumatoid arthritis | 3 | Investing.com | ||
| 16.10.25 | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update | 347 | GlobeNewswire (Europe) | Prioritization of refractory rheumatoid arthritis (RA) as lead indication for AlloNK® development FDA Fast Track Designation received for AlloNK in refractory RA, representing the first drug candidate... ► Artikel lesen | |
| 07.08.25 | Artiva Biotherapeutics GAAP EPS of -$0.87 misses by $0.06 | 2 | Seeking Alpha | ||
| 06.08.25 | Artiva Biotherapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 06.08.25 | Artiva Biotherapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.08.25 | Artiva Biotherapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.05.25 | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT ... | 177 | GlobeNewswire (Europe) | 64% (9/14) complete response rate with AlloNK + rituximab in heavily pretreated patients that were naïve to prior CAR-T cell therapy, in line with approved auto-CAR-T therapies in aggressive B-NHL... ► Artikel lesen | |
| 08.05.25 | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights | 340 | GlobeNewswire (Europe) | IND clearance and initiation of global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren's disease, idiopathic inflammatory myopathies and systemic sclerosis ... ► Artikel lesen | |
| 08.04.25 | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer | 825 | GlobeNewswire (Europe) | SAN DIEGO, April 08, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies... ► Artikel lesen | |
| 24.03.25 | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights | 239 | GlobeNewswire (Europe) | Initial data for AlloNK® from autoimmune program expected H1 2025 Updated clinical data from Phase 1/2 trial exploring AlloNK + rituximab in NHL showing continued durability of response to be presented... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 84,60 | -1,34 % | BYD gegen Tesla! KI-Profiteure BioNTech und Rio Tinto Partner Aspermont! Aktien für 2026? | Paukenschlag kurz vor Silvester! BYD hat Tesla vom E-Auto-Thron gestoßen. Die Chinesen sind jetzt auch Weltmarktführer bei rein elektrischen Fahrzeugen. Doch die Aktie hat 2025 klar enttäuscht. Ein... ► Artikel lesen | |
| AMGEN | 282,85 | -3,32 % | Amgen übernimmt Dark Blue für bis zu 840 Millionen Dollar | DJ Amgen übernimmt Dark Blue für bis zu 840 Millionen Dollar
Von Colin Kellaher
DOW JONES--Amgen hat das britische Biotechnologieunternehmen Dark Blue Therapeutics für bis zu 840 Millionen... ► Artikel lesen | |
| NOVAVAX | 6,310 | -3,22 % | Novavax, Inc.: Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights | Total revenue of $70 million in the third quarter of 2025
Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date... ► Artikel lesen | |
| BIOGEN | 159,40 | -0,44 % | Mizuho hebt Kursziel für Biogen auf 207 Dollar an und verweist auf verbesserte Aussichten für 2026 | ||
| MAINZ BIOMED | 1,175 | 0,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed gibt Rückblick auf die Highlights des Jahres 2025 | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomed gibt Rückblick auf die Highlights des Jahres 2025
05.01.2026 / 14:15 CET/CEST
Für den... ► Artikel lesen | |
| VIKING THERAPEUTICS | 27,290 | -1,57 % | Viking Therapeutics-Aktie: Hopp oder top? | Die Aktie von Viking Therapeutics steht exemplarisch für die enorme Dynamik im Markt für Abnehmmedikamente und spiegelt zugleich die noch ungelösten Bewertungsfragen im Biotech-Sektor wider. Trotz deutlicher... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 8,974 | +3,51 % | Intellia Stock Declines Around 55% in 3 Months: Here's Why | ||
| TEMPUS AI | 58,50 | -2,50 % | TD Cowen Reaffirms Hold Rating on Tempus AI (TEM), Cites the Company's Position to be a Leader | ||
| BIOCRYST PHARMACEUTICALS | 6,596 | -2,69 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| BIOMARIN PHARMACEUTICAL | 51,60 | -1,71 % | Veeva Systems Expands Long-Term Partnership With BioMarin Pharmaceutical | WASHINGTON (dpa-AFX) - Veeva Systems Inc. (VEEV) and BioMarin Pharmaceutical Inc. (BMRN) on Thursday announced a long-term enterprise agreement that extends their existing relationship.Under... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 19,820 | -1,25 % | Leerink Partners maintains Market Perform rating on Sarepta stock ahead of 2026 data | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,773 | -4,32 % | PacBio and UC Davis Researchers Introduce CiFi, a New Long-Read 3C Method That Enables Chromosome-Scale Assemblies from a Single SMRT Cell | ||
| EXELIXIS | 37,490 | -5,21 % | What 10 Analyst Ratings Have To Say About Exelixis | ||
| CARDIOL THERAPEUTICS | 0,879 | +2,21 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
17.12.2025 / 14:38 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| VAXART | 0,410 | +24,24 % | Vaxart, Inc.: Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results | Entered into an exclusive license agreement with Dynavax for the Company's COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment... ► Artikel lesen |
ARTIVA BIOTHERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,010 (-0,22 %) liegt der Kurs bei 4,590 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARTIVA BIOTHERAPEUTICS INC finden Sie auf Wallstreet Online.